课题基金 / 基金详情

Canadian Cell Therapies Workshop 2019

Canadian Cell Therapies Workshop 2019
2019 年加拿大细胞疗法研讨会
批准号：
391921
负责人：
Hay Annette
金额：
$0.73万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Miscellaneous Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-09-01 至 2019-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=391921&lang=en
关键词：
Cancer Car-T Cells Cell Manufacturing Cellular Therapy Planning Meeting

项目摘要

项目成果

Hay Annette的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
With cancer immunotherapy "coming of age", cell-based treatments have emerged as a standard-of-care for leukemia and lymphoma. The next research advance will come from further discovery, development, and optimization of these cell-based therapies. Cellula
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
海外基金